Reversing The Impact of Type II Diabetes

The Center for Disease Control has stated that 80% of all heart disease, stroke, and type 2 diabetes incidents, as well as more than 40% of cancer incidents, could be prevented if Americans stopped using tobacco, ate healthier foods, and exercised regularly.

In support of the CDC’s health mission, we are running clinical trials to test solutions to solve the chronic disease problem. Our first trial explored the possibility of treating and reversing the effects of Type II Diabetes. As part of the trial we set out to prove whether we could enable patients in:

  • Taking their medication on time, all the time
  • Developing eating habits around healthy, appropriately portioned foods
  • Exercising more frequently and with greater intensity
  • Employing consumer-grade sensors and smart phones to provide just-in-time support

Diabetes Trial 1

Over the 3-month trial, Wellsmith captured over 17,000 sensor data points per patient. These critical data help to optimize subsequent trials for solving the Type II Diabetes problem.

Future Clinical Trials

Wellsmith dreams big. Improving the lives of those with chronic diseases isn’t a moonshot, it’s a real, human possibility.

We are currently running a clinical trial for people with Type II Diabetes who are non-insulin dependent. Within the next year, we intend to conduct trials to benefit people suffering from Chronic Obstructive Pulmonary Disease (COPD) and Congestive Heart Failure (CHF).

As our research and development progresses, we will expand the core Wellsmith solutions to address other chronic diseases. Future trials may include help for those suffering from Arthritis, Irritable Bowel Syndrome, and Hyper-tension, and will benefit those who are impacted by obesity, pre-diabetes, and high cholesterol. Wellsmith’s unique capabilities within a Digital Care Plan around medication, food, and fitness, will provide those restricted by chronic disease the opportunity to experience a better, more healthful future.

Sign Up to be kept informed of future clinical trials: